glydo lidocaine hydrochloride 20 mg/mL Jelly
Other active recalls for Lidocaine Hydrochloride (different manufacturers) — 6 · tap to view
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Antiarrhythmic class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
- It's best to avoid using two lidocaine products at the same time unless your doctor says it's okay. When you use multiple products containing a local anesthetic, the total amount a...
- Can I use a lidocaine patch and a lidocaine cream at the same time?
- No — please don't do this. Heat significantly increases how much lidocaine is absorbed through your skin, which can push drug levels in your blood higher than they should be. Stick...
- Can I put a heating pad on the area where I applied a lidocaine patch?
Patient education
Supplement & herbal interactions
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 3NXW29V3WO
Hypromellose is a plant-based thickener made from cellulose. It's used in medicines as a binder to hold ingredients together, a coating for tablets, and a thickener for liquids.
-
UNII 55X04QC32I
A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
2 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.887 | $53.23 / 60 ml |
| Medicaid paysCMS SDUD · 12 mo | $1.51 | $90.79 / 60 ml |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Lidocaine Hydrochloride 20 mg/mL 76329-3013-05 | International | 25 vials | $0.704 | AT | Availability likely | save 21% |
| glydo 20 mg/mLthis 25021-0673-76 | Sagent | 10 syringes | $0.887 | AT | Availability likely | — |
| Lidocaine Hydrochloride 20 mg/mL 76329-3011-05 | International | 25 vials | $1.167 | AT | Availability likely | +32% |
| Lidocaine Hydrochloride 20 mg/mL 76329-3012-05 | International | 25 vials | $1.167 | AT | Availability likely | +32% |
| Lidocaine Hydrochloride 20 mg/mL 00404-9898-10 | Henry | 1 vial | — | AT | FDA listed | — |
| Lidocaine Hydrochloride 20 mg/mL 00404-9899-20 | Henry | 1 vial | — | AT | FDA listed | — |
| Lidocaine Hydrochloride 20 mg/mL 00404-9900-05 | Henry | 1 vial | — | AT | FDA listed | — |
| First Aid Only Lidocaine Hydrochloride Analgesic Burn Gel 20 mg/g 00924-5004-00 | Acme | 3.5 g | — | — | FDA listed | — |
| First Aid Only Burn 20 mg/g 00924-5010-00 | Acme | 3.5 g | — | — | FDA listed | — |
| Burn 20 mg/g 43473-0048-01 | Nantong | 9 g | — | — | FDA listed | — |
| PO First Aid Series BURN 2 g/100g 43473-0062-01 | Nantong | 9 g | — | — | FDA listed | — |
| JJ Care BURN 2 g/100g 43473-0069-01 | Nantong | 9 g | — | — | FDA listed | — |
| Lightning X Burn Relief Gel 2 g/100g 43473-0121-01 | Nantong | 9 g | — | — | FDA listed | — |
| Medi-First Burn 20 mg/g 47682-0477-69 | Unifirst | 6 packets | — | — | FDA listed | — |
| Lidocaine Hci 20 mg/mL 51662-1389-01 | HF | 5 ml | — | AT | FDA listed | — |
| Lidocaine Hydrochloride 20 mg/mL 51662-1551-03 | HF | 25 pouches | — | AT | FDA listed | — |
| Lidocaine Hydrochloride 20 mg/mL 51662-1552-03 | HF | 25 pouches | — | AT | FDA listed | — |
| Burn Ease 2 g/100g 58228-2010-01 | ProStat | 25 packets | — | — | FDA listed | — |
| PROSTAT FIRST AID Burn Ease, 0.9g 2 g/100g 58228-2012-01 | ProStat | 25 packets | — | — | FDA listed | — |
| Burn Ease Cooling 2 g/100g 58228-2893-05 | ProStat | 2000 packets | — | — | FDA listed | — |
| Burn Ease 2 g/100g 58228-3831-02 | ProStat | 20 packets | — | — | FDA listed | — |
| Burn Ease 2 g/100g 58228-3832-02 | ProStat | 6 packets | — | — | FDA listed | — |
| PS-3866 Burn Ease, 0.9g 2 g/100g 58228-3866-01 | ProStat | 10 packets | — | — | FDA listed | — |
| PROSTAT FIRST AID Burn Ease, 0.9g 2 g/100g 58228-3867-01 | ProStat | 10 packets | — | — | FDA listed | — |
| Burn Ease, 3.5g 2 g/100g 58228-3883-01 | ProStat | 2000 packets | — | — | FDA listed | — |
| PS-3885 Burn Ease, 3.5g 2 g/100g 58228-3885-01 | ProStat | 6 packets | — | — | FDA listed | — |
| Burn Ease 2 g/100g 58228-6210-01 | Front | 25 packets | — | — | FDA listed | — |
| FL Burn Ease, 0.9g 2 g/100g 58228-6212-01 | ProStat | 25 packets | — | — | FDA listed | — |
| Burn Ease 3.5g 2 g/100g 58228-6231-01 | Front | 20 packets | — | — | FDA listed | — |
| Burn Ease 3.5g 2 g/100g 58228-6232-01 | Front | 6 packets | — | — | FDA listed | — |
| Burn Ease 3.5g 2 g/100g 58228-6283-01 | Front | 2000 packets | — | — | FDA listed | — |
| Lidoease 2% 20 mg/g 59088-0221-03 | PureTek | 28.35 g | — | — | FDA listed | — |
| Burn Jel 2 g/100mL 59898-0200-11 | Water-Jel | 24 bottles | — | — | FDA listed | — |
| Lidocaine Hydrochloride 20 mg/g 61010-5000-00 | Safetec | 3.3 g | — | — | FDA listed | — |
| Aloe Ice Sunburn Relief 2 g/100mL 61477-0101-11 | Aloe | 60 ml | — | — | FDA listed | — |
| Regenecare Ha 20 mg/g 66977-0107-03 | MPM | 85 g | — | — | FDA listed | — |
| XeroBurn Burn Gel 2 g/100g 67777-0129-02 | Dynarex | 1728 packets | — | — | FDA listed | — |
| Burn Gel .02 g/g 69396-0106-09 | Trifecta | 144 packets | — | — | FDA listed | — |
| Redicare Burn Gel 20 mg/g 71105-0500-02 | Redicare | 15 packets | — | — | FDA listed | — |
| Jelcaine Sterile 20 mg/mL 71351-0025-30 | Brookfield | 30 ml | — | — | FDA listed | — |
| Lidocaine 20 mg/mL 72485-0611-10 | ARMAS | 1 tube | — | AT | FDA listed | — |
| Lidocaine Hydrochloride 20 mg/mL 76329-3015-05 | International | 25 vials | — | AT | FDA listed | — |
| Burn 20 mg/g 82942-1001-01 | J&A | 9 g | — | — | FDA listed | — |
| Lidomax 20 mg/g 85477-0304-07 | Oncora | 85 g | — | — | FDA listed | — |
| Collavera 20 mg/g 85477-0305-07 | Oncora | 28.33 g | — | — | FDA listed | — |
| Lidocaine Hydrochloride 2% 2 g/100g 87236-0015-35 | Aldermed | 25 packets | — | — | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
🗺️ Medicaid utilization & spend
💊 Medicaid utilization by pack size
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
📦 Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Status |
|---|---|---|---|---|---|
| 25021-0673-76 You're viewing this | 10 SYRINGE in 1 CARTON (25021-673-76) / 6 mL in 1 SYRINGE | $0.8871 / mL | $53.23 | 2014-09-15 | Active |
| 25021-0673-77 | 10 SYRINGE in 1 CARTON (25021-673-77) / 11 mL in 1 SYRINGE | $0.5189 / mL | $57.08 | 2014-09-15 | Active |
Per mL, this pack runs about 71% above the cheapest pack (NDC 25021-0673-77, $0.5189 vs $0.8871 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 66% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in NDC 25021-0673-76?
What NDC number is used to bill for this package of glydo lidocaine hydrochloride 20 mg/mL Jelly?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE GLYDO (lidocaine HCl jelly) 2% is an amide local anesthetic indicated: for prevention and control of pain in procedures involving the male and female urethra for topical treatment of painful urethritis as an anesthetic lubricant for oral and nasal endotracheal intubation GLYDO (lidocaine HCl jelly) 2% contains lidocaine, an amide local anesthetic, and is indicated in adult patients: for prevention and control of pain in procedures involving the male and female urethra ( 1 ) for topical treatment of painful urethritis ( 1 ) as an anesthetic lubricant for oral and nasal endotracheal intubation ( 1 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION The toxic effects of local anesthetics are additive. When using this product concomitantly with other lidocaine-containing products, consider the total dose of lidocaine and monitor patients for cardiovascular and respiratory vital signs. ( 2.1 ) For surface anesthesia of male adult urethra: 15 mL (300 mg lidocaine HCl) followed by additional 15 mL if needed ( 2.2 ) For surface anesthesia of female adult urethra: 3 mL to 5 mL (60 mg to 100 mg lidocaine HCl) ( 2.3 ) For lubrication for endotracheal intubation: sufficient amount to coat the external surface of endotracheal tube ( 2.4 ) For pediatric patients: Not more than 4.5 mg/kg body weight of lidocaine HCl ( 2.5 )
2.1Important Dosage and Administration Information Administration Precautions The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects related to local anesthetic systemic toxicity when additional local anesthetics are administered with GLYDO (lidocaine HCl jelly) 2% [see Warnings and Precautions ( 5.1 ), Adverse Reactions ( 6 ), Overdosage ( 10 )] . The dosage varies and depends upon the area to be anesthetized, vascularity of the tissues, individual tolerance, and the technique of anesthesia.
The lowest dosage needed to provide effective anesthesia should be administered. Dosages should be reduced for children and for elderly and debilitated patients. Although the incidence of adverse effects with GLYDO (lidocaine HCl jelly) 2% is quite low, caution should be exercised, particularly when employing large amounts, since the incidence of adverse effects is directly proportional to the total dose of local anesthetic agent administered.
No more than 600 mg of lidocaine HCl should be given in any 12 hour period.
2.2For Surface Anesthesia of the Male Adult Urethra Slowly instill approximately 15 mL (300 mg of lidocaine HCl) into the urethra. Apply a penile clamp for several minutes at the corona. An additional dose of not more than 15 mL (300 mg) can be instilled if needed.
Prior to sounding or cystoscopy, a penile clamp should be applied for 5 to 10 minutes to obtain adequate anesthesia. A total dose of 30 mL (600 mg) is usually required to fill and dilate the male urethra. Prior to catheterization, 5 mL to 10 mL (100 mg to 200 mg) are recommended for lubrication.
2.3For Surface Anesthesia of the Female Adult Urethra Slowly instill approximately 3 mL to 5 mL (60 mg to 100 mg of lidocaine HCl) into the urethra. In order to obtain adequate anesthesia, wait for several minutes prior to performing urological procedures. If desired, some jelly may be deposited on a cotton swab and introduced into the urethra.
2.4Lubrication for Endotracheal Intubation Apply a sufficient amount of jelly to coat the external surface of the endotracheal tube shortly before use. Care should be taken to avoid introducing the product into the lumen of the tube. Do not use the jelly to lubricate endotracheal stylettes.
(see WARNINGS and ADVERSE REACTIONS concerning rare reports of inner lumen occlusion). It is also recommended that use of endotracheal tubes with dried jelly on the external surface be avoided for lack of lubricating effect.
2.5Dosing for Pediatric Patients A maximum dose of GLYDO (lidocaine HCl jelly) 2% for children varies based on age and weight. The maximum dose should not exceed 4.5 mg/kg of body weight. For children over 3 years of age, the maximum dose is determined by the child's age and weight.
For example, in a child of 5 years weighing approximately 23 kg, the dose of lidocaine hydrochloride should not exceed approximately 75 mg to 100 mg (3.3 mg/kg to 4.4 mg/kg). The lowest effective dose should be used.
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS GLYDO (lidocaine HCl jelly, USP) 2% in: 120 mg per 6 mL Prefilled Syringe 220 mg per 11 mL Prefilled Syringe 120 mg per 6 mL Prefilled Syringe ( 3 ) 220 mg per 11 mL Prefilled Syringe ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS Known hypersensitivity to any local anesthetic agent of the amide-type or to other components of GLYDO 2% Jelly ( 4.1 ) Infected and/or Severely Traumatized Mucosa ( 4.2 ) Severe shock or heart block ( 4.3 )
4.1Hypersensitivity GLYDO 2% Jelly is contraindicated in patients with a known history of hypersensitivity to lidocaine or to any local anesthetics of the amide type or to other components of GLYDO 2% Jelly.
4.2Use on Infected and/or Severely Traumatized Mucosa GLYDO 2% Jelly should not be used on infected and/or severely traumatized mucosa in the area of application.
4.3Use in Severe Shock or Heart Block GLYDO 2% Jelly should not be used in patients with severe shock or heart block.
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Dose-Related Toxicity : follow dosing instructions carefully. ( 5.1 ) Methemoglobinemia : Cases have been reported in association with local anesthetics use. See full prescribing information for more details on managing these risks.
( 5.2 ) Familial Malignant Hyperthermia : Monitoring of patients is recommended ( 5.3 ) Endotracheal Tube Occlusion : Avoid introduction of jelly into the lumen of the endotracheal tube ( 5.4 ) Risk of Aspiration and Biting Trauma with Oral Use : Food and chewing gum should not be taken while the mouth or throat area is anesthetized ( 5.7 )
5.1Dose-Related Toxicity The safety and effectiveness of GLYDO 2% Jelly depends on proper dosage, correct technique, adequate precautions, and readiness for emergencies [see Adverse Reactions ( 6 )]. Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient's state of consciousness should be performed after application of GLYDO 2% Jelly. Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness.
Delay in proper management of dose-related toxicity, underventilation from any cause, and/or altered sensitivity may lead to the development of acidosis, cardiac arrest, and, possibly, death. Use the lowest dosage that results in effective anesthesia to avoid high plasma levels and serious adverse effects. Repeated doses of lidocaine may cause significant increases in blood levels with each repeated dose because of slow accumulation of the drug or its metabolites.
Tolerance to elevated blood levels varies with the status of the patient. Debilitated, elderly patients, acutely ill patients, and children should be given reduced doses commensurate with their age and physical status. Patients and healthcare providers should be instructed to strictly adhere to the recommended dosage and administration guidelines as set forth in this package insert.
The management of serious adverse reactions may require the use of resuscitative equipment, oxygen, and other resuscitative drugs.
5.2Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition [see Drug Interactions ( 7.2 )] . If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.
Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue GLYDO 2% Jelly and any other oxidizing agents.
Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.
5.3Familial Malignant Hyperthermia Many drugs used during the conduct of anesthesia are considered potential triggering agents for familial malignant hyperthermia. Since it is not known whether amide-type local anesthetics may trigger this reaction and since the need for supplemental general anesthesia cannot be predicted in advance, it is suggested that a standard p…
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following adverse reactions associated with the use of GLYDO 2% Jelly were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse experiences following the administration of lidocaine are similar in nature to those observed with other amide local anesthetic agents.
A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage or slow metabolic degradation. The most commonly encountered acute adverse reactions that demand immediate counter measures were related to the CNS and the cardiovascular system. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage or rapid absorption, or may result from a hypersensitivity, idiosyncrasy, or diminished tolerance on the part of the patient.
Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported. There have been rare reports of endotracheal tube occlusion associated with the presence of dried jelly residue in the inner lumen of the tube.
Most common adverse reactions are as follows: Central Nervous System : Lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. ( 6 ) Cardiovascular System : Bradycardia, hypotension, and cardiovascular collapse. ( 6 ) Allergic : Cutaneous lesions, urticaria, edema or anaphylactoid reactions.
( 6 ) Neurologic : Positional headaches, hypotension and backache. ( 6 ) Hematologic : Methemoglobinemia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Nervous System Disorders Adverse reactions were characterized by excitation and/or depression of the central nervous system and included lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression, and arrest. The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest.
Drowsiness following the administration of lidocaine is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption. Cardiac Disorders High doses have led to high plasma levels and related depression of the myocardium, decreased cardiac output, heartblock, hypotension, bradycardia, and cardiovascular collapse, which may lead to cardiac arrest. Immune System Disorders Allergic reactions are characterized by cutaneous lesions, urticaria, edema, or anaphylactoid reactions.
Allergic reactions may occur as a result of sensitivity either to the local anesthetic agent or to other components in the formulation.
🔄 Drug Interactions ▾
7 DRUG INTERACTIONS Local Anesthetics : The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered ( 7.1 ). Drugs Associated with Methemoglobinemia : Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs ( 7.2 ).
Hepatic Impairment : Consider reduced dosing and increased monitoring for local anesthetic systemic toxicity in patients with hepatic impairment ( 8.6 )
7.1Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with GLYDO 2% Jelly cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Warnings and Precautions ( 5.1 )].
7.2Drugs Associated with Methemoglobinemia Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia: Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastics Agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase, Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate, Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS Pediatric Use : Dose should be reduced commensurate with age, body weight and physical condition ( 8.4 )
8.1Pregnancy Risk Summary Available published data and decades of clinical use with GLYDO 2% Jelly in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Local anesthetics may cause varying degrees of toxicity to the mother and fetus and adverse reactions include alterations of the central nervous system, peripheral vascular tone and cardiac function [see Clinical Considerations ]. There was no evidence of teratogenicity when lidocaine was administered to pregnant rats and rabbits subcutaneously at 0.8 and 0.16 times, respectively, the maximum recommended human dose (MRHD) of 600 mg during the period of organogenesis.
In a published animal reproduction study, pregnant rats administered lidocaine by continuous subcutaneous infusion at 8 times the MRHD during the period of organogenesis resulted in lower fetal body weights [see Data ] . The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Maternal adverse reactions During treatment of systemic toxicity, which may appear as maternal hypotension or fetal bradycardia, the parturient should be maintained in the left lateral decubitus position if possible or manual displacement of the uterus off the great vessels be accomplished. Elevating the patient's legs will also help prevent decreases in blood pressure.
The fetal heart rate also should be monitored continuously, and electronic fetal monitoring is highly advisable. Labor or delivery Local anesthetics rapidly cross the placenta and can cause varying degrees of maternal, fetal and neonatal toxicity [see Clinical Pharmacology ( 12.3 )] . The incidence and degree of toxicity depend upon the procedure performed, the type and amount of drug used, and the technique of drug administration.
Adverse reactions in the parturient, fetus and neonate involve alterations of the central nervous system, peripheral vascular tone, and cardiac function. However, dosage recommendations for local anesthesia are much lower than dosage recommendations for other major blocks. Data Animal Data Reproduction studies for lidocaine have been performed in both rats and rabbits.
There was no evidence of harm to the fetus when pregnant rats were given subcutaneous doses of up to 50 mg/kg lidocaine (approximately 0.8 times the MRHD of 600 mg based on body surface area (BSA) comparison) during the period of organogenesis. In addition, there was no evidence of harm to the fetus when pregnant rabbits were given a subcutaneous dose of 5 mg/kg (approximately 0.16 times the MRHD based on BSA comparison) during the period of organogenesis. Treatment of pregnant rabbits with 25 mg/kg (approximately 0.8 times the MRHD based on BSA comparison) produced evidence of maternal toxicity and evidence of delayed fetal development, including a non-significant decrease in fetal weight (7%) and an increase in minor skeletal anomalies (skull and sternebral defect, reduced ossification of the phalanges).
The effect of lidocaine on post-natal development was examined in rats by treating pregnant female rats daily subcutaneously at doses of 2, 10, and 50 mg/kg (approximately 0.03, 0.16, and 0.8 times, respectively, the MRHD based on BSA comparison) from Day 15 of pregnancy and up to 20 days postpartum. No signs of adverse effects were seen either in dams or in the pups up to and including the dose of 10 mg/kg; however, the number of surviving pups was reduced at 50 mg/kg, both at birth and the duration of lactation period, the effe…
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary Available published data and decades of clinical use with GLYDO 2% Jelly in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Local anesthetics may cause varying degrees of toxicity to the mother and fetus and adverse reactions include alterations of the central nervous system, peripheral vascular tone and cardiac function [see Clinical Considerations ]. There was no evidence of teratogenicity when lidocaine was administered to pregnant rats and rabbits subcutaneously at 0.8 and 0.16 times, respectively, the maximum recommended human dose (MRHD) of 600 mg during the period of organogenesis.
In a published animal reproduction study, pregnant rats administered lidocaine by continuous subcutaneous infusion at 8 times the MRHD during the period of organogenesis resulted in lower fetal body weights [see Data ] . The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Maternal adverse reactions During treatment of systemic toxicity, which may appear as maternal hypotension or fetal bradycardia, the parturient should be maintained in the left lateral decubitus position if possible or manual displacement of the uterus off the great vessels be accomplished. Elevating the patient's legs will also help prevent decreases in blood pressure.
The fetal heart rate also should be monitored continuously, and electronic fetal monitoring is highly advisable. Labor or delivery Local anesthetics rapidly cross the placenta and can cause varying degrees of maternal, fetal and neonatal toxicity [see Clinical Pharmacology ( 12.3 )] . The incidence and degree of toxicity depend upon the procedure performed, the type and amount of drug used, and the technique of drug administration.
Adverse reactions in the parturient, fetus and neonate involve alterations of the central nervous system, peripheral vascular tone, and cardiac function. However, dosage recommendations for local anesthesia are much lower than dosage recommendations for other major blocks. Data Animal Data Reproduction studies for lidocaine have been performed in both rats and rabbits.
There was no evidence of harm to the fetus when pregnant rats were given subcutaneous doses of up to 50 mg/kg lidocaine (approximately 0.8 times the MRHD of 600 mg based on body surface area (BSA) comparison) during the period of organogenesis. In addition, there was no evidence of harm to the fetus when pregnant rabbits were given a subcutaneous dose of 5 mg/kg (approximately 0.16 times the MRHD based on BSA comparison) during the period of organogenesis. Treatment of pregnant rabbits with 25 mg/kg (approximately 0.8 times the MRHD based on BSA comparison) produced evidence of maternal toxicity and evidence of delayed fetal development, including a non-significant decrease in fetal weight (7%) and an increase in minor skeletal anomalies (skull and sternebral defect, reduced ossification of the phalanges).
The effect of lidocaine on post-natal development was examined in rats by treating pregnant female rats daily subcutaneously at doses of 2, 10, and 50 mg/kg (approximately 0.03, 0.16, and 0.8 times, respectively, the MRHD based on BSA comparison) from Day 15 of pregnancy and up to 20 days postpartum. No signs of adverse effects were seen either in dams or in the pups up to and including the dose of 10 mg/kg; however, the number of surviving pups was reduced at 50 mg/kg, both at birth and the duration of lactation period, the effect most likely being secondary to maternal toxicity.
No other effects on litter size, litter weight, abnormalities in the pups and phys…
🧒 Pediatric Use ▾
8.4Pediatric Use Although the safety and effectiveness of GLYDO 2% Jelly in pediatric patients have not been established, a study of 19 premature neonates (gestational age <33 weeks) found no correlation between the plasma concentration of lidocaine or monoethylglycinexylidide and infant body weight when moderate amounts of lidocaine (i.e. 0.3 mL/kg of lidocaine gel 20 mg/mL) were used for lubricating both intranasal and endotracheal tubes. No neonate had plasma levels of lidocaine above 750 mcg/L.
Dosages in children should be reduced, commensurate with age, body weight, and physical condition [see Dosage and Administration ( 2 )] .
🧓 Geriatric Use ▾
8.5Geriatric Use Elderly patients should be given reduced doses commensurate with their age and physical condition.
🆘 Overdosage ▾
10 OVERDOSAGE Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics [see Warnings and Precautions ( 5 ) and Adverse Reactions ( 6 )] . The use of this product concomitantly with other lidocaine products should be done with caution and appropriate patient monitoring. Management of Local Anesthetic Emergencies The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient's state of consciousness after each local anesthetic administration.
At the first sign of change, oxygen should be administered. The first step in the management of convulsions consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask. Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated, keeping in mind that drugs used to treat convulsions sometimes depress the circulation when administered intravenously.
Should convulsions persist despite adequate respiratory support, and if the status of the circulation permits, a benzodiazepine (such as diazepam) may be administered intravenously. The clinician should be familiar, prior to use of local anesthetics, with these anticonvulsant drugs. Supportive treatment of circulatory depression may require administration of intravenous fluids and, when appropriate, a vasopressor as directed by the clinical situation (e.g., ephedrine).
If not treated immediately, both convulsions and cardiovascular depression can result in hypoxia, acidosis, bradycardia, arrhythmias, and cardiac arrest. If cardiac arrest should occur, standard cardiopulmonary resuscitative measures should be instituted. Endotracheal intubation, employing drugs and techniques familiar to the clinician, may be indicated, after initial administration of oxygen by mask; if difficulty is encountered in the maintenance of a patient airway or if prolonged ventilatory support (assisted or controlled) is indicated.
Dialysis is of negligible value in the treatment of acute overdosage with lidocaine.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
12.2Pharmacodynamics The onset of action is 3 to 5 minutes. It is ineffective when applied to intact skin. Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure.
These changes may be attributable to a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system. Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of lidocaine hydrochloride required to produce overt systemic effects. Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6 mcg free base per mL.
In the rhesus monkey arterial blood levels of 18 to 21 mcg/mL have been shown to be threshold for convulsive activity.
12.3Pharmacokinetics Absorption Lidocaine may be absorbed following topical administration to mucous membranes, its rate and extent of absorption depending upon concentration and total dose administered, the specific site of application, and duration of exposure. In general, the rate of absorption of local anesthetic agents following topical application occurs most rapidly after intratracheal administration. Lidocaine is also well-absorbed from the gastrointestinal tract, but little intact drug may appear in the circulation because of biotransformation in the liver.
Distribution The plasma binding of lidocaine is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 mcg of free base per mL, 60 to 80 percent of lidocaine is protein bound. Binding is also dependent on the plasma concentration of the alpha-l-acid glycoprotein.
Lidocaine crosses the blood-brain and placental barriers, presumably by passive diffusion. Elimination Lidocaine is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation.
N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of lidocaine. Approximately 90% of lidocaine administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged.
The primary metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline. Studies of lidocaine metabolism following intravenous bolus injections have shown that the elimination half-life of this agent is typically 1.5 to 2 hours. Because of the rapid rate at which lidocaine is metabolized, any condition that affects liver function may alter lidocaine kinetics.
The half-life may be prolonged twofold or more in patients with liver dysfunction. Renal dysfunction does not affect lidocaine kinetics but may increase the accumulation of metabolites.
🧬 Mechanism of Action ▾
12.1Mechanism of Action Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING GLYDO ® (lidocaine HCl jelly, USP) 2% is supplied as follows: NDC GLYDO ® (lidocaine HCl jelly, USP) 2% Package Factor (20 mg per mL) 25021-673-76 120 mg per 6 mL Single-Dose Prefilled Syringe 10 syringes per carton 25021-673-77 220 mg per 11 mL Single-Dose Prefilled Syringe 10 syringes per carton Storage Conditions Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Discard unused portion. Sterile, Preservative-free, PVC-free.
The container and container closure are not made with natural rubber latex.
📦 Storage and Handling ▾
Storage Conditions Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Discard unused portion. Sterile, Preservative-free, PVC-free. The container and container closure are not made with natural rubber latex.
📋 Description ▾
11 DESCRIPTION GLYDO (lidocaine HCl jelly, USP) 2% is a sterile aqueous product that contains a local anesthetic agent and is administered topically (see INDICATIONS AND USAGE for specific uses). GLYDO (lidocaine HCl jelly, USP) 2% contains lidocaine HCl which is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, monohydrochloride, the molecular weight is 270.8. The molecular formula is C 14 H 23 ClN 2 O, and has the following structural formula: GLYDO (lidocaine HCl jelly, USP) 2% also contains hypromellose, and the resulting mixture maximizes contact with mucosa and provides lubrication for instrumentation.
The unused portion should be discarded after initial use. Composition of GLYDO (lidocaine HCl jelly, USP) 2% 6 mL or 11 mL syringes: Each mL contains 20 mg of lidocaine HCl. The formulation also contains hypromellose, and sodium hydroxide to adjust pH to 6.0 to 7.0.
Figure
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION
17.1Allergic-Type Reactions Assess if the patient has had allergic-type reactions to amide-type local anesthetics or to other formulation ingredients [see Contraindications ( 4 ), Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6 )] .
17.2Methemoglobinemia Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to stop use and seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue [see Warnings and Precautions ( 5.2 )] .
17.3Risk of Aspiration When topical anesthetics are used in the mouth, the patient should be aware that the production of topical anesthesia may impair swallowing and thus enhance the danger of aspiration. For this reason, food should not be ingested for 60 minutes following use of local anesthetic preparations in the mouth or throat area. This is particularly important in children because of their frequency of eating.
17.4Risk of Biting Trauma Numbness of the tongue or buccal mucosa may enhance the danger of unintentional biting trauma. Food and chewing gum should not be taken while the mouth or throat area is anesthetized. Brands listed are the trademarks of their respective owners. sagent ® Mfd. for SAGENT Pharmaceuticals Schaumburg, IL 60173 (USA) Mfd. by Klosterfrau Berlin GmbH Made in Germany ©2025 Sagent Pharmaceuticals Revised: May 2025